Direct intravitreal administration of these agents mitigates the issues of poor bioavailability, however short half‐lives relative to duration of therapy results in a requirement for frequent high dose administrations.

Journal of Clinical & Experimental Ophthalmology

O peptides and proteins remain a significant challenge for sustained or controlled delivery. Many of these agents have been clinically validated in ophthalmology with great success as exemplified by Macugen®, Eylea® and Lucentis®. However, there remains a critical unmet medical need to sustain or target the delivery of these agents. The clinical application of macromolecule drug substances is limited due to poor bioavailability and disposition. Direct intravitreal administration of these agents mitigates the issues of poor bioavailability, however short half‐lives relative to duration of therapy results in a requirement for frequent high dose administrations.

Direct intravitreal administration of these agents mitigates the issues of poor bioavailability, however short half‐lives relative to duration of therapy results in a requirement for frequent high dose administrations.

Non-degradable and biodegradable implants